Biologic therapies are essential in the acute management of MIS-C, as they selectively inhibit key inflammatory pathways—such as IL-1, IL-6, and TNF-α signaling—to modulate the hyperimmune response and prevent multisystem complications [70, 109, 110]. This evidence concerns the gene IL6 and COVID-19–associated multisystem inflammatory syndrome in children.